de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. - Via assessing the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19, researchers sought to determine if inhibitors of the renin–angiotensin–aldosterone system (RAAS) could predispose individuals to severe COVID-19. Data were collected for 1,139 cases [444 (39·0%) females; mean age 69·1 years] and 11,390 population controls. Despite being matched on gender and age, a significantly higher proportion of cases had preexisting cardiovascular disease and risk factors than did controls. No increase in the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to intensive care units, was observed in correlation with receiving RAAS inhibitors, and hence these should not be discontinued to prevent a severe case of COVID-19. .